Invesco reports Q1 2026 results on May 21 with a notably more constructive analyst setup than it carried into any recent quarter.
The most striking feature of the pre-earnings tape is a near-unanimous wave of upward target revisions following its last earnings call. JP Morgan's Kenneth Worthington, Goldman Sachs' Alexander Blostein, TD Cowen's Bill Katz, Evercore ISI's Glenn Schorr, and Barclays' Benjamin Budish all raised targets on April 29 — just days after each had been cutting them through early-to-mid April. That reversal is sharp. Goldman went from $27 to $30 in a single session after trimming from $30 to $27 weeks earlier. The consensus target now rests near $29.14, roughly 7% above the current price of $27.12 — a modest but positive gap that squares with the stock's 10% one-month rally. Most of the Street remains at Hold-equivalent ratings, meaning the revisions signal relief rather than outright conviction.
The short side tells a calmer story. Short interest runs at 4.1% of the free float — moderate for an asset manager — and has actually fallen 12% over the past week after spiking earlier in May. Borrow availability is generous, and the cost to borrow remains negligible at just 0.48%, even though it has crept up roughly 15% week-on-week and 23% over the past month. The ORTEX short score of 40.6 sits in the bottom third of the universe, placing IVZ well away from any squeeze-pressure territory. Days to cover is under two, and availability has not meaningfully tightened, leaving the lending market loose ahead of the print.
Options positioning offers the clearest near-term caution signal. The put/call ratio has moved to 0.10 — above its 20-day average of 0.08 and about 1.3 standard deviations elevated. That said, the absolute level remains low relative to the 52-week high of 0.64, so the skew reflects mild pre-earnings hedging rather than genuine fear. The stock gave back 2.2% on Friday and is down roughly 1.7% on the week, a modest pullback that peers broadly shared — BLK, GS, MS, and EVR all fell between 1% and 4% on the day, suggesting sector-level selling rather than Invesco-specific concern.
Fundamentally, the debate centers on revenue quality and AUM trajectory. The most recent quarter showed $1.74 billion in revenue, up 14% year-on-year, with a net income margin near 15.4% and EV/EBITDA of around 12x — not demanding for a firm of its scale. The forward EPS growth factor ranks in the 71st percentile, and the dividend score of 73 reflects a still-meaningful yield, though the dividend data in the snapshot is stale and should be verified independently. Bears will point to a price/book near 1.3x with negative tangible book, high debt-to-equity, and a business model that remains sensitive to market levels and flows. Bulls will cite the sharp analyst target recovery as evidence that last quarter's execution reassured a skeptical Street.
The May 21 print will test whether Invesco's AUM base and fee revenue held up through the quarter's market volatility — and whether the Street's rapid pivot to higher targets was justified or premature.
See the live data behind this article on ORTEX.
Open IVZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
